AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 25 mg three times a day
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 35 mg three times a day
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 50 mg three times a day
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 60 mg three times a day
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 75 mg three times a day
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 90 mg three times a day
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 100 mg three times a day
Trial: 8522637
Drug: Xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline tartrate 115 mg three times a day
Trial: 6459255
Drug: HNN cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HNN cream (halcinonide, neomycin, and nystatin)
Trial: 6459255
Drug: BGI cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGI cream (betamethasone valerate, gentamicin, iodochlorhydroxyquin, and tolnaftate)
Trial: 6459255
Drug: HNN cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HNN cream
Trial: 6459255
Drug: BGI cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGI cream
Trial: 26331880
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (0.325 g/kg)
Trial: 26331880
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (0.65 g/kg)
Trial: 26331880
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration (0.00 g/kg)
Trial: 26331880
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (0.00 g/kg)
Trial: 26529118
Drug: Escitalopram 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 30 mg
Trial: 19730388
Drug: Escitalopram (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (both doses)
Trial: 15190235
Drug: Gabapentin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (up to a maximum dose of 2,400 mg/d in three doses)
Trial: 1839998
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral preparation of medroxyprogesterone acetate (200‐mg sachet, twice daily)
Trial: 1839998
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation (Farlutal, 500‐mg tablet, twice daily)
Trial: 1839998
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral preparation of medroxyprogesterone acetate
Trial: 19387901
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (ARB) - losartan (25‐50 mg, n = 5), candesartan (4‐8 mg, n = 4), valsartan (80 mg, n = 1), telmisartan (40 mg, n = 2), olmesartan (10 mg, n = 1)
Trial: 15293073
Drug: Conventional influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional influenza split vaccine (SpV)
Trial: 15293073
Drug: MF59‐adjuvanted subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59‐adjuvanted subunit vaccine (aSuV)
Trial: 15293073
Drug: Virosome‐based subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosome‐based subunit vaccine (vSuV)
Trial: 3245857
Drug: Bezafibrate sustained
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the morning
Trial: 3245857
Drug: Bezafibrate sustained
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the evening
Trial: 26093863
Drug: High-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose statin recapture therapy given orally 12 and 2 hours before CABG
Trial: 26093863
Drug: High-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose statin recapture therapy
Trial: 23732189
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (60 mg/day duloxetine + 300 mg/day pregabalin)
Trial: 23732189
Drug: High-dose monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose monotherapy (120 mg/day duloxetine or 600 mg/day pregabalin)
Trial: 26816607
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day duloxetine
Trial: 22137511
Drug: IV tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV tranexamic acid 10 mg/kg
Trial: 22137511
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water 0.1 mL/kg (placebo group)
Trial: 2321721
Drug: Caudal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal bupivacaine 0.25% (1 ml/kg)
Trial: 2321721
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 0.25 mg/kg
Trial: 6985789
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus selective intra‐arterial vasopressin infusion
Trial: 21244275
Drug: FD-APAP (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FD-APAP (2 × 500 mg tablets)
Trial: 21244275
Drug: Standard acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard acetaminophen (2 × 500 mg tablets)
Trial: 19841453
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 500 microg twice daily for 6 months
Trial: 19841453
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 500 microg twice daily for 30 months
Trial: 19841453
Drug: Fluticasone, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone, 500 microg twice daily, and salmeterol, 50 microg twice daily for 30 months
Trial: 17558758
Drug: Phosphatidylcholine-based anti-cellulite
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine-based anti-cellulite gel and LED treatments
Trial: 17558758
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel and LED treatments
Trial: 15198839
Drug: Kenalog (triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kenalog (triamcinolone acetonide) spray
Trial: 15198839
Drug: Cortizone‐10 Quick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortizone‐10 Quick Shot (hydrocortisone) spray
Trial: 15198839
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no corticosteroid spray)
Trial: 11403522
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of scheduled naps and regular bedtimes
Trial: 11403522
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stimulant medications alone)
Trial: 8458044
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg twice a day
Trial: 3023274
Drug: Nonselective beta-blockade
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective beta-blockade (BB, 80 mg propranolol)
Trial: 28057081
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV)
Trial: 28057081
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg (RSV)
Trial: 28057081
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg (FMS)
Trial: 19697997
Drug: Mangosteen dietary
RxNorm normalized name: mangostin
DrugBank: Mangostin (DB14371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangosteen dietary supplement
Trial: 11314678
Drug: MDMA (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (oral doses ranging from 70-150 mg, 1.35-1.8 mg/kg)
Trial: 9398711
Drug: Iodine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine (0.2 mg/day)
Trial: 8492053
Drug: Sensory Integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory Integration Treatment (SIT)
Trial: 2379381
Drug: Oral ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketanserin 20mg (n = 14)
Trial: 2379381
Drug: Oral ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketanserin 40mg (n = 8)
Trial: 2379381
Drug: Intravenous ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketanserin 5mg (n = 4)
Trial: 4809462
Drug: 1 (2
RxNorm normalized name: RIBOCICLIB 200MG TAB,21 (200MG)DAILY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 (2 chloroethyl) 3 (4 methylcyclohexyl) 1 nitrosourea (methyl CCNU) at a dosage of 225 mg/sq m p.o. on day 1
Trial: 4809462
Drug: Combination program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination program utilizing 5 fluorouracil, cyclophosphamide, and prednisone with or without vincristine
Trial: 4809462
Drug: Cross over
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross over to methyl CCNU after initial treatment failure
Trial: 4809462
Drug: Cross over
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross over to the combination program after initial treatment failure
Trial: 4809462
Drug: Combination programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination programs
Trial: 4809462
Drug: Vincristine (part
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (part of the combination program)
Trial: 27723955
Drug: Salt room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt room with halogenerator (treatment group)
Trial: 19192459
Drug: Combination lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination lithium carbonate/nortriptyline
Trial: 18455084
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg/d
Trial: 16649891
Drug: Radial shock-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radial shock-wave therapy (RSWT)
Trial: 16649891
Drug: Less active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less active similar therapy (Control)
Trial: 7619662
Drug: L-365,260 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260 (10 mg, 50 mg p.o.)
Trial: 2793453
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 mg every 8 hours)
Trial: 25447269
Drug: Preservative-free fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% (once daily)
Trial: 8371918
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% (twice daily)
Trial: 25447269
Drug: Tafluprost 0.0015%
RxNorm normalized name: TAFLUPROST 0.0015% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafluprost 0.0015% (once daily)
Trial: 25447269
Drug: Preservative-free fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5%
Trial: 22114059
Drug: Combined Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Therapy (CT) applied once a week (G1)
Trial: 22114059
Drug: Combined Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Therapy (CT) applied twice a week (G2)
Trial: 17980977
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg sodium nitrate for 28 days
Trial: 16354890
Drug: Progestin‐only pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin‐only pill
Trial: 11942868
Drug: Intravenous ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketoprofen 2 mg/kg
Trial: 11942868
Drug: Intramuscular ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ketoprofen 2 mg/kg
Trial: 11942868
Drug: Placebo (intramuscular)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular)
Trial: 11942868
Drug: Placebo (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (both intravenous and intramuscular)
Trial: 9794747
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bendrofluazide daily
Trial: 9794747
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg bendrofluazide daily
Trial: 9794747
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bendrofluazide every other day
Trial: 876437
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of amoxycillin (3 g for adults and 100 mg/kg for children)
Trial: 3887254
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of amoxycillin
Trial: 6981162
Drug: Single-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose therapy
Trial: 27782976
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) using oral magnesium citrate
Trial: 25565485
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of fish oil (240 mg EPA + 240 mg DHA) with a multivitamin
Trial: 25565485
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of fish oil (480 mg EPA + 480 mg DHA) with a multivitamin
Trial: 25565485
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of fish oil without a multivitamin
Trial: 23831445
Drug: Heparin-bonded covered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded covered stents (Viabahn)
Trial: 21411235
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment for comorbid SUD and PTSD
Trial: 15334286
Drug: 10 microgrammes
RxNorm normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microgrammes recombinant hepatitis B vaccine
Trial: 15334286
Drug: 20 microgrammes
RxNorm normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microgrammes recombinant hepatitis B vaccine
Trial: 9710861
Drug: Optimal cut
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal cut point of 18.3 mL.kg-1.min-1
Trial: 9710861
Drug: VO2 <
RxNorm normalized name: The full generic name for the drug abbreviation 'VO2 <' is not readily available. This abbreviation does not appear to be a standard drug name or abbreviation. It is more likely a measurement or parameter related to oxygen consumption or exercise physiology, rather than a specific drug. Without more context about the clinical trial data, I cannot provide the full generic name for this abbreviation.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VO2 < 18 mL.kg-1.min-1
Trial: 1836989
Drug: 22 G
RxNorm normalized name: Empty Carpuject 2 mL 22 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 G spinal needle
Trial: 1836989
Drug: 4.5 g
RxNorm normalized name: Zosyn 4.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g iodine
Trial: 24332248
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (LD ASA)
Trial: 24332248
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (HD ASA)
Trial: 10231869
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of growth hormone (GH) and low-dose estrogen (ethinyl estradiol, 5 micrograms/d) in girls with Turner syndrome.
Trial: 10231869
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) alone in girls with Turner syndrome.
Trial: 10231869
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) alone in adults with Turner syndrome.
Trial: 10231869
Drug: Estrogen (ethinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (ethinyl estradiol, 50 micrograms/d) and progesterone in combination with GH in adults.
Trial: 9193221
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin and fluorouracil) plus radiation therapy
Trial: 1493838
Drug: Nifedipine 60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 60 mg once daily
Trial: 3554553
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg in 5 ml saline, repeated on demand)
Trial: 3554553
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine (10 mg on request)
Trial: 30149366
Drug: nab‐paclitaxel, gemcitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab‐paclitaxel, gemcitabine, cisplatin and oral capecitabine (PAXG; arm A; N = 26)
Trial: 22582765
Drug: Individual cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive-behavioral therapy (I-CBT)
Trial: 17545008
Drug: Novel immunosuppressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel immunosuppressive agents and established immunosuppressive agents
Trial: 17545008
Drug: Newer immunosuppressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer immunosuppressive agents (proliferation signal inhibitors)
Trial: 17545008
Drug: Costimulatory pathway
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costimulatory pathway inhibitors and other new immunosuppressive agents
Trial: 16213136
Drug: Intravaginal micronised
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal micronised progesterone 200 mg three times daily (n=351)
Trial: 16213136
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone 10 mg twice daily (n=79)
Trial: 8536446
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol 50 micrograms/norethindrone 1 mg
Trial: 8536446
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol 35 micrograms/norethindrone 1 mg
Trial: 8536446
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol 35 micrograms/norethindrone 0.5 mg
Trial: 28027641
Drug: Wolfberry Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wolfberry Extract (WBE) - 13.5 g in 80 mL pouch, consumed after one meal per day for 8 weeks
Trial: 23570290
Drug: DSL v5
RxNorm normalized name: Immunitor V5
DrugBank: Tubimod (DB17745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSL v5 prescription